CO2022014154A2 - Formulaciones farmacéuticas de profármacos de adrenomedulina a base de polietilenglicol y uso - Google Patents

Formulaciones farmacéuticas de profármacos de adrenomedulina a base de polietilenglicol y uso

Info

Publication number
CO2022014154A2
CO2022014154A2 CONC2022/0014154A CO2022014154A CO2022014154A2 CO 2022014154 A2 CO2022014154 A2 CO 2022014154A2 CO 2022014154 A CO2022014154 A CO 2022014154A CO 2022014154 A2 CO2022014154 A2 CO 2022014154A2
Authority
CO
Colombia
Prior art keywords
adrenomedullin
polyethylene glycol
pharmaceutical formulations
prodrugs
peg
Prior art date
Application number
CONC2022/0014154A
Other languages
English (en)
Inventor
Florian Unger
Stefan Christian Schneid
Hans-Walter Motzkus
Carina Haasbach
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CO2022014154A2 publication Critical patent/CO2022014154A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a nuevas formulaciones farmacéuticas, preferentemente para inhalación, que comprenden profármacos de adrenomedulina a base de polietilenglicol (PEG) (PEG–ADM), y a su uso para el tratamiento y/o la prevención de lesión pulmonar aguda/síndrome de dificultad respiratoria aguda (ALI/SDRA).
CONC2022/0014154A 2020-04-03 2022-10-03 Formulaciones farmacéuticas de profármacos de adrenomedulina a base de polietilenglicol y uso CO2022014154A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20168075 2020-04-03
PCT/EP2021/058428 WO2021198328A1 (en) 2020-04-03 2021-03-31 Pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use

Publications (1)

Publication Number Publication Date
CO2022014154A2 true CO2022014154A2 (es) 2022-10-31

Family

ID=70189768

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0014154A CO2022014154A2 (es) 2020-04-03 2022-10-03 Formulaciones farmacéuticas de profármacos de adrenomedulina a base de polietilenglicol y uso

Country Status (18)

Country Link
US (1) US20230364245A1 (es)
EP (1) EP4126061A1 (es)
JP (1) JP2023520543A (es)
KR (1) KR20220163413A (es)
CN (1) CN115666654A (es)
AU (1) AU2021247501A1 (es)
BR (1) BR112022017588A2 (es)
CA (1) CA3177217A1 (es)
CL (1) CL2022002639A1 (es)
CO (1) CO2022014154A2 (es)
CR (1) CR20220500A (es)
DO (1) DOP2022000212A (es)
EC (1) ECSP22077374A (es)
IL (1) IL297014A (es)
JO (1) JOP20220251A1 (es)
MX (1) MX2022012318A (es)
PE (1) PE20231070A1 (es)
WO (1) WO2021198328A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6085740A (en) 1996-02-21 2000-07-11 Aerogen, Inc. Liquid dispensing apparatus and methods
US6235177B1 (en) 1999-09-09 2001-05-22 Aerogen, Inc. Method for the construction of an aperture plate for dispensing liquid droplets
WO2003059424A1 (en) 2002-01-15 2003-07-24 Aerogen, Inc. Methods and systems for operating an aerosol generator
JOP20190001B1 (ar) 2011-11-03 2022-03-14 Bayer Pharma AG عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه

Also Published As

Publication number Publication date
ECSP22077374A (es) 2022-11-30
CR20220500A (es) 2022-11-18
WO2021198328A1 (en) 2021-10-07
KR20220163413A (ko) 2022-12-09
PE20231070A1 (es) 2023-07-17
MX2022012318A (es) 2022-10-27
DOP2022000212A (es) 2022-10-31
US20230364245A1 (en) 2023-11-16
CL2022002639A1 (es) 2023-04-10
EP4126061A1 (en) 2023-02-08
CA3177217A1 (en) 2021-10-07
BR112022017588A2 (pt) 2022-10-18
IL297014A (en) 2022-12-01
AU2021247501A1 (en) 2022-10-27
CN115666654A (zh) 2023-01-31
JP2023520543A (ja) 2023-05-17
JOP20220251A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
CY1125329T1 (el) Αντιιικες ενωσεις πυραζολο- και τριαζολο-πυριμιδινης εναντι toy rsv
SV2018005778A (es) Derivados aromaticos de sulfonamida
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CO2018009382A2 (es) Eliminación del virus de la hepatitis b con agentes antivirales
CL2019002744A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
PE20151867A1 (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados
CO2022014073A2 (es) Compuestos antivirales y métodos para la administración de los mismos
CL2019003294A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
UY33479A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento
CL2011002494A1 (es) Compuestos derivados de 7-aza-di-espiro-[3.0.4.1]-decan-8-carboxamida; composición farmacéutica que los comprenden; y uso para el tratamiento de un trastorno asociado con el virus de la hepatitis c (hcv) y el virus de inmunodeficiencia humana (vih).
CY1116759T1 (el) Ανθελονοσιακη φαρμακευτικη συνθεση
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP21042554A (es) Proteínas f de prefusión del vrs estabilizadas
BR112017006842A2 (pt) formulação de rapamicina inalável para o tratamento de hipertensão pulmonar
AR093382A1 (es) Dispositivo de administracion de farmacos para el tratamiento de pacientes con enfermedades respiratorias
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
ECSP10010164A (es) Formulaciones de polvo seco que comprenden derivados del ácido ascórbico
ECSP22005485A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
CO2022014154A2 (es) Formulaciones farmacéuticas de profármacos de adrenomedulina a base de polietilenglicol y uso
CO2022014155A2 (es) Formulaciones farmacéuticas líquidas de profármacos a base de polietilenglicol de adrenomedulina y su uso
UY30934A1 (es) Producto farmacéutico combinacion de un antagonista del receptor de quimioquina 1 (ccr1) y un antagonista muscarinico, composiciones farmacéuticas y aplicaciones.
CL2023000682A1 (es) Composicion farmaceutica que comprende cloroquina y usos de la misma.
UY39811A (es) Inhibidores de proteasas para el tratamiento de infecciones por coronavirus